Fig. 2From: Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort studyKaplan-Meier survival curves for subgroups according to the risk scores. The median overall survivals were 19.0 months in group A (score ≤ 5, solid black line), 11.2 months in group B (score 6, dashed line), and 6.1 months in group C (score ≥ 7, dotted line) (P < 0.001, log-rank test)Back to article page